Newsroom
Healthcare
Drugs, devices, payers, and the business of health.
HHS did not disclose how much of its $1.07 billion Medicaid deferral was new
HHS said on July 21 that it was deferring about $867.5 million for California and $199 million for Minnesota. Its public release did not identify the reporting quarters, deferral numbers or reconciliation needed to separate newly deferred expenditures from amounts represented in earlier actions, leaving both the unique total and the currently unpaid balance unknown. [HHS](https://www.hhs.gov/press-room/hhs-defers-medicaid-payments-california-minnesota-fraud-review.html) [Associated Press](https://apnews.com/article/medicaid-fraud-minnesota-california-oz-rfk-trump-24033ef9807b46f8b6fd6614ef5b1169)
Canada widened its Ebola entry rule without quantifying the added risk reduction
Canada will prohibit foreign nationals who were in the Democratic Republic of the Congo during the previous 21 days from entering beginning at 11:59 p.m. EDT on July 20. The available model covers measures already operating before the prohibition, while public records do not disclose how many additional travelers the new rule excludes or how much importation risk it removes.
Taylor Farms listed lettuce distribution in 27 states, but the traceability benefit cannot be measured
Federal investigators linked a five-state Cyclospora outbreak to shredded iceberg lettuce supplied to Taco Bell by Taylor Farms de Mexico, while the supplier listed recalled product distribution in 27 states. The published record does not contain the investigation timestamps, actual recordkeeping baseline, restaurant-level removal times or serving counts needed to determine whether full Food Traceability Rule compliance would have accelerated removal by three days or reduced implicated servings by 10 percent.
The public record does not show how the FTC reached its $13 billion Caremark savings ceiling
The FTC says its proposed Caremark settlement could preserve or produce up to $13 billion in patient savings over ten years. The public can reproduce one multiplication, but not the baselines, enrollment, adoption or cost-offset assumptions needed to estimate how much benefit the order would actually cause.
AstraZeneca's Wainua Missed. The Harder Question Is Whether the Molecule or the Yardstick Moved.
On 9 July 2026 AstraZeneca and Ionis said their heart drug Wainua missed its main goal in a Phase III trial, erasing about $27bn of AstraZeneca's value. The same release reportedly showed a benefit in patients taking the drug alone and none in those also on a newer 'stabiliser' drug that barely existed when the trial was designed. That pattern is consistent with two very different stories, a shifting comparison group, or a genuinely weaker molecule, and the evidence does not yet cleanly pick between them.
The $425,000 Newcomer: IgA Nephropathy's Sixth Drug Priced Near the Top, and the Proof Isn't What Bought the Premium
On July 7, 2026 the FDA cleared Vera Therapeutics' atacicept as the sixth disease-modifying drug for IgA nephropathy, at a $425,000 list price second only to the class's most expensive drug. Ranking all six shows the ladder tracks how new and how novel-in-mechanism a drug is more than the strength of its proven kidney benefit: the two full-approval drugs are the two cheapest, and the newer biologics list far above an independent value benchmark, while the two full-approval drugs sit closest to it. The catch that keeps this honest: the single priciest drug also has confirmed benefit, so proof plainly is not what commands the premium either way.
Vertex Paid $8.8 Billion for Crinetics. Most of the Growth It Bought Is a Drug It Can't Sell Yet.
On July 6, 2026, Vertex agreed to buy Crinetics for about $8.8 billion net of cash, its largest deal ever. Reconstructing Vertex's own peak-sales pitch shows most of the combined revenue potential rides on atumelnant, an unapproved Phase 3 candidate, not on PALSONIFY, the launched acromegaly pill running at roughly $41 million a year. That is where the growth sits, not proof Vertex overpaid: paying up for a pipeline is normal, and the finding is about locating the bet.
The 9-0 Loss That Came Back Deeper: CMS Now Proposes Paying 340B Drugs 37% Less, and the Survey Is Why
On 2 July 2026, CMS proposed paying 340B hospitals average sales price minus 33.4 percent for outpatient drugs, a deeper cut than the ASP minus 22.5 percent the Supreme Court struck 9-0 in 2022. The analysis finds CMS could cut deeper precisely because it ran the acquisition-cost survey the Court had demanded, and that budget neutrality recycles the entire cut back into other payments, so the real story is redistribution across hospitals and patients, not net savings for anyone.
The 100% Drug Tariff Where the 100% Hits Almost Nothing
On July 31 the US switches on a Section 232 pharmaceutical tariff with a 100% headline rate on patented medicines. Rebuild the $213.8B import base lane by lane using the proclamation's own carve-outs, and the full 100% reaches only a sliver of the value, while the average tariff actually collected lands around 8 percent. The headline rate is a lever to extract drug-pricing concessions, not a levy built to collect, though the tariff overall still bills importers billions, and a scheduled ratchet points upward.
The copay that leaves no trace: Medicare's new $50 GLP-1 deal charges the sick and the poor the most
Medicare's first weight-loss drug benefit went live July 1 with a flat $50 monthly copay, but the payment is booked outside Part D's out-of-pocket ledger. That design makes the deal a bargain for the healthiest eligible enrollees and a $450-to-$600-a-year surcharge for beneficiaries who hit the $2,100 drug cap or rely on the Extra Help low-income subsidy.
The ACA Premium Spike Is Mostly Sticky Care Cost. Only a Thin Policy Slice Can Round-Trip.
Insurers requested their largest average increase in more than five years for 2026 coverage, an estimated 26%, and early 2027 filings point to a second straight double-digit year. A decomposition of the typical request shows only about 4 percentage points are the kind of reversible, subsidy-driven markup that a credit extension could refile away before the 12 August window closes. The rest is locked-in medical cost growth, and the healthy enrollees the markup was hedging against have largely already left.
Did Merck just call the bottom of the life-science tools slump, or overpay for it?
On 25 June 2026 Germany's Merck agreed to buy Bio-Techne for about $11.3bn, roughly 9.3 times sales, even though the target now grows at about half its pre-pandemic pace. Rebuilding the price from the filings shows the deal looks expensive measured against revenue but ordinary measured against profit once promised savings land, so the whole case rests on two numbers not yet in the accounts: cost synergies and a growth re-acceleration the revenue line does not yet show.
